ARCA Biopharma Inc., a clinical development stage biopharmaceutical company, is actively engaged in the development and commercialization of genetically targeted therapies for cardiovascular diseases. With its flagship product Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist, the company has successfully completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. In addition to Gencaro, ARCA Biopharma Inc. is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is currently in Phase IIb clinical trial for the treatment of COVID-19. A proud recipient of a collaboration agreement with LabCorp, ARCA Biopharma Inc. is developing a genetic test for the GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.